ADINAZOLAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H18ClN5
Molecular Weight	351.833
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12

InChI

InChIKey=GJSLOMWRLALDCT-UHFFFAOYSA-N

InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C19H18ClN5
Molecular Weight	351.833
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6320036 | https://www.ncbi.nlm.nih.gov/pubmed/3298327 | https://www.ncbi.nlm.nih.gov/pubmed/9600717 | https://www.ncbi.nlm.nih.gov/pubmed/27535017

Adinazolam, a benzodiazepine agonist, is an effective anxiolytic agent with antidepressant properties. It was shown, that adinazolam by itself had relatively weak benzodiazepine agonist activity, and much of the pharmacological activity belonged to its active metabolite N-desmethyladinazolam (NDMAD). Adinazolam has never been FDA approved, but it is sold as a research chemical.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6148400	Agonist 2678

PubMed

Title	Date	PubMed
Benzodiazepine suppression of corticotropin-releasing factor (CRF)-induced beta-endorphin release from rat neurointermediate pituitary.	1992 Sep-Oct	1480515
Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers.	1993	8131152
A follow-up study of DSM-III-R generalized anxiety disorder with syndromal and subsyndromal major depression.	2003 Feb	12547291
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.	2003 Feb 28	12600700
Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.	2007 Jul	17481865
The effect of sympathetic antagonists on the antidepressant action of alprazolam.	2008 Jun 1	21499463
The enduring effects of an adolescent social stressor on synaptic density, part II: Poststress reversal of synaptic loss in the cortex by adinazolam and MK-801.	2008 Mar	18081181
Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.	2009 Jun	19430911

Patents

Sample Use Guides

In Vivo Use Guide

from 90 to 40 mg/day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:45:49 UTC 2023` Edited by `admin` on `Sat Dec 16 17:45:49 UTC 2023`
Record UNII	KN08449444
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ADINAZOLAM

Official Name

English

ADINAZOLAM [MI]

Common Name

English

U-41,123

Code

English

Adinazolam [WHO-DD]

Common Name

English

4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE-1-METHANAMINE, 8-CHLORO-N-N-DIMETHYL-6-PHENYL-

Common Name

English

U-41123

Code

English

adinazolam [INN]

Common Name

English

8-Chloro-1-[(dimethylamino)methyl]-6-phenyl-4H-S-triazolo[4,3-a][1,4]benzodiazepine

Systematic Name

English

ADINAZOLAM [USAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN05BA07